PubMed:32673060 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":932,"end":937},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.\nBACKGROUND: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nOBJECTIVE: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nDESIGN: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nSETTING: Internet-based trial across the United States and Canada (40 states and 3 provinces).\nPARTICIPANTS: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nINTERVENTION: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.\nRESULTS: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P \u003c 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).\nLIMITATIONS: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nCONCLUSION: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE: Private donors."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"T2","span":{"begin":141,"end":165},"obj":"Disease"},{"id":"T3","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"T4","span":{"begin":244,"end":252},"obj":"Disease"},{"id":"T5","span":{"begin":594,"end":602},"obj":"Disease"},{"id":"T6","span":{"begin":615,"end":623},"obj":"Disease"},{"id":"T7","span":{"begin":1154,"end":1163},"obj":"Disease"},{"id":"T8","span":{"begin":1169,"end":1216},"obj":"Disease"},{"id":"T9","span":{"begin":1169,"end":1202},"obj":"Disease"},{"id":"T10","span":{"begin":1218,"end":1226},"obj":"Disease"},{"id":"T11","span":{"begin":1305,"end":1314},"obj":"Disease"},{"id":"T12","span":{"begin":1960,"end":1968},"obj":"Disease"},{"id":"T13","span":{"begin":2152,"end":2160},"obj":"Disease"},{"id":"T14","span":{"begin":2322,"end":2330},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.\nBACKGROUND: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nOBJECTIVE: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nDESIGN: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nSETTING: Internet-based trial across the United States and Canada (40 states and 3 provinces).\nPARTICIPANTS: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nINTERVENTION: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.\nRESULTS: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P \u003c 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).\nLIMITATIONS: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nCONCLUSION: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE: Private donors."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":66,"end":67},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":178,"end":187},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T3","span":{"begin":358,"end":360},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T4","span":{"begin":882,"end":886},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T5","span":{"begin":905,"end":909},"obj":"http://purl.obolibrary.org/obo/CLO_0001550"},{"id":"T6","span":{"begin":1026,"end":1029},"obj":"http://purl.obolibrary.org/obo/CLO_0054064"},{"id":"T7","span":{"begin":1060,"end":1061},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":1270,"end":1271},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":1863,"end":1865},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T10","span":{"begin":2163,"end":2170},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T11","span":{"begin":2194,"end":2201},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.\nBACKGROUND: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nOBJECTIVE: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nDESIGN: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nSETTING: Internet-based trial across the United States and Canada (40 states and 3 provinces).\nPARTICIPANTS: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nINTERVENTION: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.\nRESULTS: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P \u003c 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).\nLIMITATIONS: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nCONCLUSION: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE: Private donors."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":212,"end":230},"obj":"Chemical"},{"id":"T2","span":{"begin":698,"end":716},"obj":"Chemical"},{"id":"T3","span":{"begin":1062,"end":1067},"obj":"Chemical"},{"id":"T4","span":{"begin":1449,"end":1467},"obj":"Chemical"},{"id":"T5","span":{"begin":1656,"end":1674},"obj":"Chemical"},{"id":"T6","span":{"begin":1837,"end":1855},"obj":"Chemical"},{"id":"T7","span":{"begin":2016,"end":2034},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.\nBACKGROUND: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nOBJECTIVE: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nDESIGN: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nSETTING: Internet-based trial across the United States and Canada (40 states and 3 provinces).\nPARTICIPANTS: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nINTERVENTION: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.\nRESULTS: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P \u003c 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).\nLIMITATIONS: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nCONCLUSION: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE: Private donors."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":0,"end":18},"obj":"Chemical"},{"id":"3","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"30","span":{"begin":141,"end":165},"obj":"Disease"},{"id":"31","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"32","span":{"begin":212,"end":230},"obj":"Chemical"},{"id":"33","span":{"begin":244,"end":252},"obj":"Disease"},{"id":"34","span":{"begin":518,"end":530},"obj":"Species"},{"id":"35","span":{"begin":594,"end":602},"obj":"Disease"},{"id":"36","span":{"begin":615,"end":623},"obj":"Disease"},{"id":"37","span":{"begin":698,"end":716},"obj":"Chemical"},{"id":"38","span":{"begin":1030,"end":1038},"obj":"Species"},{"id":"39","span":{"begin":1154,"end":1163},"obj":"Disease"},{"id":"40","span":{"begin":1169,"end":1216},"obj":"Species"},{"id":"41","span":{"begin":1218,"end":1228},"obj":"Species"},{"id":"42","span":{"begin":1305,"end":1314},"obj":"Disease"},{"id":"43","span":{"begin":1449,"end":1467},"obj":"Chemical"},{"id":"44","span":{"begin":1633,"end":1645},"obj":"Species"},{"id":"45","span":{"begin":1656,"end":1674},"obj":"Chemical"},{"id":"46","span":{"begin":1814,"end":1826},"obj":"Species"},{"id":"47","span":{"begin":1837,"end":1855},"obj":"Chemical"},{"id":"48","span":{"begin":1960,"end":1968},"obj":"Disease"},{"id":"49","span":{"begin":2004,"end":2009},"obj":"Disease"},{"id":"50","span":{"begin":2016,"end":2034},"obj":"Chemical"},{"id":"51","span":{"begin":2087,"end":2092},"obj":"Disease"},{"id":"52","span":{"begin":2130,"end":2142},"obj":"Species"},{"id":"53","span":{"begin":2152,"end":2162},"obj":"Species"},{"id":"54","span":{"begin":2225,"end":2243},"obj":"Chemical"},{"id":"55","span":{"begin":2322,"end":2330},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"tao:has_database_id","subj":"2","obj":"MESH:D006886"},{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C000657245"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"MESH:C000657245"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:C000657245"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:D006886"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:C000657245"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Tax:9606"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:C000657245"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:C000657245"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D006886"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"Tax:9606"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:D007239"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:2697049"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Tax:2697049"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D007239"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D006886"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"Tax:9606"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D006886"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:9606"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D006886"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:C000657245"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D003643"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D006886"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:D003643"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:2697049"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D006886"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.\nBACKGROUND: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nOBJECTIVE: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nDESIGN: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nSETTING: Internet-based trial across the United States and Canada (40 states and 3 provinces).\nPARTICIPANTS: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nINTERVENTION: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.\nRESULTS: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P \u003c 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).\nLIMITATIONS: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nCONCLUSION: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE: Private donors."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":65},"obj":"Sentence"},{"id":"T2","span":{"begin":66,"end":85},"obj":"Sentence"},{"id":"T3","span":{"begin":86,"end":97},"obj":"Sentence"},{"id":"T4","span":{"begin":98,"end":177},"obj":"Sentence"},{"id":"T5","span":{"begin":178,"end":188},"obj":"Sentence"},{"id":"T6","span":{"begin":189,"end":283},"obj":"Sentence"},{"id":"T7","span":{"begin":284,"end":291},"obj":"Sentence"},{"id":"T8","span":{"begin":292,"end":422},"obj":"Sentence"},{"id":"T9","span":{"begin":423,"end":431},"obj":"Sentence"},{"id":"T10","span":{"begin":432,"end":517},"obj":"Sentence"},{"id":"T11","span":{"begin":518,"end":531},"obj":"Sentence"},{"id":"T12","span":{"begin":532,"end":678},"obj":"Sentence"},{"id":"T13","span":{"begin":679,"end":692},"obj":"Sentence"},{"id":"T14","span":{"begin":693,"end":820},"obj":"Sentence"},{"id":"T15","span":{"begin":821,"end":830},"obj":"Sentence"},{"id":"T16","span":{"begin":831,"end":938},"obj":"Sentence"},{"id":"T17","span":{"begin":939,"end":1013},"obj":"Sentence"},{"id":"T18","span":{"begin":1014,"end":1022},"obj":"Sentence"},{"id":"T19","span":{"begin":1023,"end":1108},"obj":"Sentence"},{"id":"T20","span":{"begin":1109,"end":1381},"obj":"Sentence"},{"id":"T21","span":{"begin":1382,"end":1601},"obj":"Sentence"},{"id":"T22","span":{"begin":1602,"end":1755},"obj":"Sentence"},{"id":"T23","span":{"begin":1756,"end":1909},"obj":"Sentence"},{"id":"T24","span":{"begin":1910,"end":2010},"obj":"Sentence"},{"id":"T25","span":{"begin":2011,"end":2104},"obj":"Sentence"},{"id":"T26","span":{"begin":2105,"end":2117},"obj":"Sentence"},{"id":"T27","span":{"begin":2118,"end":2212},"obj":"Sentence"},{"id":"T28","span":{"begin":2213,"end":2224},"obj":"Sentence"},{"id":"T29","span":{"begin":2225,"end":2331},"obj":"Sentence"},{"id":"T30","span":{"begin":2332,"end":2355},"obj":"Sentence"},{"id":"T31","span":{"begin":2356,"end":2371},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.\nBACKGROUND: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nOBJECTIVE: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nDESIGN: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nSETTING: Internet-based trial across the United States and Canada (40 states and 3 provinces).\nPARTICIPANTS: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nINTERVENTION: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.\nRESULTS: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P \u003c 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).\nLIMITATIONS: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nCONCLUSION: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE: Private donors."}

{"project":"maxiaofeng52_800_3","denotations":[{"id":"T1","span":{"begin":0,"end":18},"obj":"CI"},{"id":"T2","span":{"begin":212,"end":230},"obj":"CI"},{"id":"T3","span":{"begin":698,"end":716},"obj":"CI"},{"id":"T4","span":{"begin":1449,"end":1467},"obj":"CI"},{"id":"T5","span":{"begin":1656,"end":1674},"obj":"CI"},{"id":"T6","span":{"begin":1837,"end":1855},"obj":"CI"},{"id":"T7","span":{"begin":2016,"end":2034},"obj":"CI"},{"id":"T8","span":{"begin":2225,"end":2243},"obj":"CI"},{"id":"T9","span":{"begin":812,"end":819},"obj":"CI"},{"id":"T10","span":{"begin":1736,"end":1743},"obj":"CI"},{"id":"T11","span":{"begin":1472,"end":1479},"obj":"CI"},{"id":"T12","span":{"begin":1889,"end":1896},"obj":"CI"},{"id":"T13","span":{"begin":1915,"end":1922},"obj":"CI"},{"id":"T14","span":{"begin":318,"end":325},"obj":"CI"},{"id":"T15","span":{"begin":56,"end":64},"obj":"DP"},{"id":"T16","span":{"begin":167,"end":175},"obj":"DP"},{"id":"T17","span":{"begin":141,"end":165},"obj":"DP"},{"id":"T18","span":{"begin":244,"end":252},"obj":"DP"},{"id":"T19","span":{"begin":594,"end":602},"obj":"DP"},{"id":"T20","span":{"begin":615,"end":623},"obj":"DP"},{"id":"T21","span":{"begin":1960,"end":1968},"obj":"DP"},{"id":"T22","span":{"begin":2322,"end":2330},"obj":"DP"}],"text":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.\nBACKGROUND: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nOBJECTIVE: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nDESIGN: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nSETTING: Internet-based trial across the United States and Canada (40 states and 3 provinces).\nPARTICIPANTS: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nINTERVENTION: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.\nRESULTS: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P \u003c 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).\nLIMITATIONS: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nCONCLUSION: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE: Private donors."}

{"project":"wangzhuo19_800_3","denotations":[{"id":"T1","span":{"begin":0,"end":18},"obj":"CI"},{"id":"T10","span":{"begin":2016,"end":2034},"obj":"CI"},{"id":"T11","span":{"begin":212,"end":230},"obj":"CI"},{"id":"T12","span":{"begin":698,"end":716},"obj":"CI"},{"id":"T13","span":{"begin":1449,"end":1467},"obj":"CI"},{"id":"T14","span":{"begin":1656,"end":1674},"obj":"CI"},{"id":"T15","span":{"begin":1837,"end":1855},"obj":"CI"},{"id":"T2","span":{"begin":2225,"end":2243},"obj":"CI"},{"id":"T3","span":{"begin":56,"end":64},"obj":"DP"},{"id":"T4","span":{"begin":167,"end":175},"obj":"DP"},{"id":"T5","span":{"begin":244,"end":252},"obj":"DP"},{"id":"T6","span":{"begin":594,"end":602},"obj":"DP"},{"id":"T7","span":{"begin":615,"end":623},"obj":"DP"},{"id":"T8","span":{"begin":1960,"end":1968},"obj":"DP"},{"id":"T9","span":{"begin":2322,"end":2330},"obj":"DP"},{"id":"T16","span":{"begin":141,"end":165},"obj":"DP"},{"id":"T17","span":{"begin":318,"end":325},"obj":"CI"},{"id":"T18","span":{"begin":812,"end":819},"obj":"CI"},{"id":"T19","span":{"begin":1472,"end":1479},"obj":"CI"},{"id":"T20","span":{"begin":1736,"end":1743},"obj":"CI"},{"id":"T21","span":{"begin":1889,"end":1896},"obj":"CI"},{"id":"T22","span":{"begin":1915,"end":1922},"obj":"CI"}],"text":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.\nBACKGROUND: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).\nOBJECTIVE: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.\nDESIGN: Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).\nSETTING: Internet-based trial across the United States and Canada (40 states and 3 provinces).\nPARTICIPANTS: Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.\nINTERVENTION: Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.\nRESULTS: Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P \u003c 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).\nLIMITATIONS: Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.\nCONCLUSION: Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.\nPRIMARY FUNDING SOURCE: Private donors."}